Abstract Library

#2932 Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO)

Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Truong Thanh X, Adelman D, Feuilly M, Houchard A, Cella D,

Keywords: Somatuline lanreotide, syringe, neuroendocrine tumors, medical treatment,

#2124 A Case Report of a Malignant Insulinoma

Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Zoumblios C, Tegos T, Kyriakopoulos G, Argyrakos T, Alevizopoulos N,

Keywords: malignant, insulinoma,

#1646 Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey Among Patients with a Neuroendocrine Tumour

Introduction: Depot somatostatin analogues (SSA) Sandostatin LAR® (SL) and Somatuline Autogel® (SA) injections, are facilitated by a professional home injection service.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Geilvoet W, Feelders R, de Herder W,

Keywords: somatostatin analogues, home injection,

#1488 Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)

Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Bartsch D, Albers M, Bollmann C, Roth S,

Keywords: chemoprevention, neuroendocrine neoplasms, somatostatin analogue ,

#1284 Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study

Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Manon A

Authors: Manon A, Wolin E, Chassaing C, Lewis A, Bertocchi L,

Keywords: lanreotide, Somatuline, pharmacokinetic, PK,